Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04654975 · ClinicalTrials.gov registry record
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
A clinical trial of Brain Metastases and Esophageal Neoplasms, sponsored by Universitaire Ziekenhuizen KU Leuven.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 8
- Study locations
NCT04654975: Recruiting study of Brain Metastases and Esophageal Neoplasms, sponsored by Universitaire Ziekenhuizen KU Leuven.
NCT04654975 is a study of Brain Metastases and Esophageal Neoplasms that is actively recruiting participants, run by Universitaire Ziekenhuizen KU Leuven. The registered enrollment target is 10,000 participants, above the 64-participant average among 67 other Brain Metastases trials with a reported enrollment target (15525% higher). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04654975, a study of Brain Metastases and Esophageal Neoplasms, is actively recruiting participants, sponsored by Universitaire Ziekenhuizen KU Leuven.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 8
- Study locations
Study Summary
Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be cured: mostly those with recurrence in one single organ. Brain metastases are rare after esophagectomy for cancer, but they have a serious impact on survival. Agressive treatment is often moren difficult for brain metastases compared to other metastases and some risk factors have been identified earlier. There is an impression that the incidence of brain metastases in esophageal cancer patients has increased since the introduction of neoadjuvant treatment schemes. However, this is not clear yet. A potential explanation could be that chemotherapy disturbs the blood-brain-barrier, hereby facilitating the migration of tumor cells to the brain. The purpose of this study is to retrospectively analyze the incidence and potential risk factors of brain metastases in patients who underwent esophagectomy for esophageal cancer. Patients treated between 2000 and 2019 will be included and outcome parameters are Odds Ratio for brain metastases (comparison between primary surgery and neoadjuvant treatment followed by surgery), time to recurrence and risk factors, number and characteristics of the brain metastases.
Conditions Studied
Interventions
- PROCEDURE Esophagectomy for esophageal cancer
Study Locations (8)
Other
- Universitair ziekenhuis Gent - Ghent
- Centre Hospitalier régional Universitaire de Lille - Lille
- Saint James Hospital - Dublin
- Amsterdam UMC - Amsterdam
- Zuyderland MC - Heerlen
- Erasmus MC - Rotterdam
- Karolinska Institutet - Stockholm
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2020-06-02 |
| Est. Completion | 2025-03-31 |
What NCT04654975 shows while recruiting
NCT04654975 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 64-participant average among 67 other Brain Metastases trials with a reported enrollment target (15525% higher).
The record links to 3 conditions, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which Esophagectomy for esophageal cancer is the first listed.
NCT04654975 lists 8 locations in 2 states (Other, Texas).
Frequently Asked Questions
What is clinical trial NCT04654975 about?
NCT04654975 is a clinical study titled "Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)". Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be cured: mostly those with recurrence in one single organ. Brain metastases...
What is the current status of trial NCT04654975?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2020-06-02. Estimated completion is 2025-03-31.
What conditions does trial NCT04654975 study?
This clinical trial studies the following conditions: Brain Metastases, Esophageal Neoplasms, Esophagectomy.
What interventions are being tested in trial NCT04654975?
The interventions under investigation include: Esophagectomy for esophageal cancer (PROCEDURE).
Who is sponsoring clinical trial NCT04654975?
This trial is sponsored by Universitaire Ziekenhuizen KU Leuven, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04654975 being conducted?
This trial has 8 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04654975's enrollment target sits among peer trials
10,000 1st of 67 higher than 67 of 67 other Brain Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
RECRUITING · NA
-
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
RECRUITING · Phase 4
-
7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI